Treating Waldenstrom’s Macroglobulinemia
Season 3, Episode 56, Dec 17, 2020, 01:48 AM
In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.
In this episode of the “CURE Talks Cancer” podcast, we spoke with r. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, also known as WM.
WM is a rare, incurable disease. Its current standards of care available consist of Rituxan (rituximab), Imbruvica (ibrutinib) combinations or monotherapy in the first- and second-line setting. However, there are no treatments currently approved for the third line.
Chanan-Khan discussed these options, as well as a novel agent, CLR 131, that is being evaluated in a phase 2 study.